Liestal, Switzerland, January 19, 2010 - Santhera Pharmaceuticals (SIX: SANN) today announced that Klaus Schollmeier, Chief Executive Officer, will present at the upcoming 4th Annual European Life Science CEO Forum For Partnering & Investing on Tuesday, January 25, 2011 at 15:00 CET. Mr. Schollmeier will also participate in a partnering panel on Wednesday, January 26, 2011 at 09:00 CET. The European Life Science CEO Forum is being held at the Radisson Blu Hotel, Zurich Airport, Switzerland.
About the European Life Sciences CEO Forum
The 4th Annual European Life Sciences CEO Forum for Partnering & Investing to be held in Zurich from January 25-26, 2011 is recognized as the leading international stage for those interested in investing in the Life Science and Biotech industries and is highly transactional, drawing together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. Following the success of last years' Life Sciences forum, the conference aims to expand the audience and provide, once again, opportunities for executive-level networking, deal-making and partnering.
* * *
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of severe neuromuscular diseases, an area of high unmet medical need which includes many orphan indications with no current therapy. Santhera's first product, Catena®, to treat Friedreich's Ataxia is marketed in Canada. For further information, please visit www.santhera.com.
Catena® is a trademark of Santhera Pharmaceuticals.
For further information, contact
Thomas Staffelbach, Head Public & Investor Relations
Phone: +41 (0)61 906 89 47
thomas.staffelbach@santhera.com
Disclaimer/Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.